Parkinson’s Study Probes Link to Ashkenazi Mutation
A study sponsored by The Michael J. Fox Foundation for Parkinson’s Research will investigate a genetic mutation found more often in Ashkenazi Jews.
The Parkinson’s Progression Markers Initiative, a large-scale biomarker study, is expanding to study individuals with genetic mutations associated with Parkinson’s disease.
Among those mutations is the LRRK2, which accounts for a greater number of Parkinson’s cases among certain ethnic populations and families, notably Jews of Eastern European descent.
The study will enroll 250 people with the LRRK2 mutation and Parkinson’s and a like number with the mutation but without Parkinson’s.
Genetic mutations account for 5 percent to 10 percent of all Parkinson’s cases, but a study of these individuals may reveal disease traits that apply to all Parkinson’s patients.
The Fox Foundation has secured 15 industry partners and co-funding sponsors for the initiative. They include Abbott Laboratories, Biogen, BMS, Covance, Eli Lilly, GE Healthcare, Genentech, GSK, Merck, Pfizer and Roche.
The study will take place at 32 clinical sites around the world.
It’s our birthday and we’re still celebrating!
We hope you appreciated this article. Before you go, we’d like to ask you to please support the Forward’s independent Jewish news.
This week we celebrate 129 years of the Forward. We’re proud of our origins as a Yiddish print publication serving Jewish immigrants. And we’re just as proud of what we’ve become today: A trusted source of Jewish news and opinion, available digitally to anyone in the world without paywalls or subscriptions.
We’ve helped five generations of American Jews make sense of the news and the world around them — and we aren’t slowing down any time soon.
As a nonprofit newsroom, reader donations make it possible for us to do this work. Support independent, agenda-free Jewish journalism and our board will match your gift in honor of our birthday!
Support our mission to tell the Jewish story fully and fairly.
